Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

(2010) Qing Sheng et al.   CANCER CELL

Receptor Tyrosine Kinase Coactivation Networks in Cancer

(2010) A. M. Xu et al.   CANCER RESEARCH

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

(2010) C. M. Annunziata et al.   CLINICAL CANCER RESEARCH

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Ovarian Low-grade and High-grade Serous Carcinoma

(2009) Russell Vang et al.   ADVANCES IN ANATOMIC PATHOLOGY

Degradation of Activated Protein Kinases by Ubiquitination

(2009) Lu Zhimin et al.   Annual Review of Biochemistry

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

(2009) Jessica N McAlpine et al.   BMC CANCER

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer

(2009) Su-Jin Baek et al.   Journal of Gynecologic Oncology

EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

(2009) Jeong-Won Lee et al.   JNCI-Journal of the National Cancer Institute

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers

(2008) Joanna Vermeij et al.   BMC CANCER

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

(2008) Y.-X. Zhang et al.   CANCER RESEARCH

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

(2008) S. A. Eccles et al.   CANCER RESEARCH

Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

(2008) Russell J. Schilder et al.   JOURNAL OF CLINICAL ONCOLOGY